Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 31;10(8):1844. doi: 10.3390/biomedicines10081844

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effect of ARNI and ivabradine on the serum level of angiotensin 1-10 (Ang I) (A), angiotensin 1-8 (Ang II) (B), angiotensin 2-8 (Ang III) (C), angiotensin 3-8 (Ang IV) (D), angiotensin 1-7 (E), angiotensin 1-5 (F), angiotensin 1-5/angiotensin 1-7 ratio (G), marker of renin activity (RA-S; Ang I + Ang II) (H), and marker of angiotensin-converting enzyme activity (ACE-S; Ang II/Ang I) (I) in SHRs after six weeks of treatment. Ang, angiotensin; ARNI, sacubitril/valsartan; C, Wistar controls; IVA, ivabradine; SHRs, spontaneously hypertensive rats. Results are presented as means ± SEM. n = 6 per group. One-way, two-tailed ANOVA followed by multiple comparisons with a Bonferroni post-hoc test; * p < 0.05 vs. C; # p < 0.05 vs. SHR.